<- Go Home
Context Therapeutics Inc.
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Market Cap
$228.8M
Volume
277.1K
Cash and Equivalents
$66.0M
EBITDA
-$39.7M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$3.62
52 Week Low
$0.49
Dividend
N/A
Price / Book Value
3.78
Price / Earnings
-6.56
Price / Tangible Book Value
3.78
Enterprise Value
$162.9M
Enterprise Value / EBITDA
-4.12
Operating Income
-$39.7M
Return on Equity
46.39%
Return on Assets
-29.79
Cash and Short Term Investments
$66.0M
Debt
$112.1K
Equity
$60.5M
Revenue
N/A
Unlevered FCF
-$19.1M
Sector
Pharmaceuticals
Category
N/A